A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2008

Conditions
Cognition DisordersMultiple Sclerosis
Interventions
DRUG

C105

Trial Locations (30)

14203

The Jacobs Neurological Institute, Buffalo

17607

Raleigh Neurology Associates, Raleigh

22908

University of Virginia, Department of Neurology, Charlottesville

23230

Neurological Associates, Inc, Richmond

25301

Capitol Neurology, Charleston

30309

Shepard Center, Atlanta

32751

Neurology Associates, PA, Maitland

33609

Axiom Clinical Research of Florida, Tampa

33701

Suncoast Neuroscience Associates, Inc., St. Petersburg

34233

Lovelace Scientific Resources, Sarasota

34243

Roskamp Institute, Sarasota

40536

University of Kentucky, Lexington

44302

Neurology & Neuroscience Associates, Inc., Akron

45242

Riverhills Healthcare, Inc, Cincinnati

48202

Henry Ford Health System, Department of Neurology, Detroit

49684

Northern Michigan Neurology, Traverse City

58103

MeritCare Neuroscience Clinic, Fargo

66160

University of Kansas Medical Center, Department of Neurology, Kansas City

66214

MidAmerica Neuroscience Institute, Lenexa

77030

Baylor College of Medicine, Houston

78229

Integra Clinical Research, San Antonio

78681

Central Texas Neurology, Round Rock

85013

Saint Joseph's Hospital, Barrow Neurology Clinics, Phoenix

85741

Northwest Neuro Specialists, PLLC, Tuscon

92354

Loma Linda University, Department of Neurology, Loma Linda

93534

Research Center for Clinical Studies West, Lancaster

06810

Associated Neurologists, P.C., Danbury

06824

Associated Neurologist of Southern Connecticut, PC, Fairfield

06510

Yale University MS Center, New Haven

02905

The Neurology Foundation, Inc., Providence

Sponsors
All Listed Sponsors
lead

Cognition Pharmaceuticals, LLC

INDUSTRY